The proposed transaction values the company at approximately $137.99 per share, a sharp climb from Thursday’s closing price of $90.38. While neither company has officially confirmed the agreement, sources familiar with the matter suggest an announcement could arrive as early as Monday. This acquisition would place Apogee’s specialized biotechnology portfolio directly under the control of the pharmaceutical giant, marking a major consolidation move within the sector.